Eisai announced an update on the regulatory review process of lecanemab by the European Medicines Agency (EMA). Additional details can be found in a news release available on Eisai’s website.
Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application
Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application
March 22, 2024
• Company Statements
May 2, 2024
Biogen Reports Progress on Corporate Responsibility Priorities
Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing progress on the company’s
April 25, 2024
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA ® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human